Axsome Therapeutics: Alzheimer's Expansion Could Drive AXSM Higher

Axsome Therapeutics (AXSM) has been making waves with its flagship drug, Auvelity, which was initially approved in 2022 for major depressive disorder. By 2025, the drug had already generated over $500 million in annual sales. Now, Axsome is expanding Auvelity into a new indication: agitation associated with Alzheimer's disease. In April, the FDA approved Auvelity for this condition, making it the first non-antipsychotic treatment for Alzheimer's-related agitation. The company launched the drug for this new indication in June.

Early numbers are encouraging. In the second quarter, Auvelity generated $180.3 million in sales, up 51% year over year. More importantly, during the first eight weeks after the Alzheimer's launch, new patient starts among people aged 65 and older jumped 126% compared to the previous quarter. This suggests strong demand from a patient population that previously had limited options.

Axsome has been preparing for this expansion. The company increased its sales force from roughly 300 to over 600 representatives to target psychiatrists, neurologists, geriatric specialists, and primary-care doctors. Insurance coverage is also robust, with approximately 89% of covered lives having access to Auvelity. Management believes the drug could eventually reach $8 billion in peak annual sales, split roughly evenly between depression and Alzheimer's agitation.

Beyond Auvelity, Axsome has two other commercial products: Sunosi for excessive daytime sleepiness and Symbravo for migraines. Sunosi generated $35.8 million in Q2 revenue, while Symbravo, though only generating $2.3 million, saw prescriptions rise 30% sequentially. The pipeline includes AXS-12 for narcolepsy (FDA decision expected May 2027) and AXS-14 for fibromyalgia, which has already produced positive Phase 3 results. Management aims to file one new FDA drug application per year through 2030.

The Alzheimer's agitation market represents a significant opportunity for Axsome. Agitation is one of the most challenging symptoms for caregivers to manage, and current treatments often involve antipsychotics, which carry serious side effects. As the first non-antipsychotic approved for this condition, Auvelity has a first-mover advantage in a space with substantial unmet need. The 126% increase in new patient starts among seniors indicates that physicians are quickly adopting the drug.

If Auvelity continues to gain traction, it could become a multibillion-dollar franchise by 2030. Axsome's management estimates peak sales of $8 billion, with half coming from Alzheimer's agitation. While this is a company estimate and not a guarantee, the early launch metrics support the potential. The expansion of the sales force and high insurance coverage further position the drug for success.

However, the company is spending heavily to commercialize its drugs. In Q2, selling, general, and administrative expenses were $208.1 million, leading to a net loss of $51.3 million despite $218.4 million in product revenue. This spending is justified if Auvelity's sales continue to scale, but it poses a risk if the Alzheimer's launch underperforms. Investors should monitor the company's path to profitability, as sustained losses could pressure the stock.

Beyond Auvelity, Axsome's pipeline offers additional growth opportunities. The potential approval of AXS-12 in 2027 and the positive Phase 3 results for AXS-14 in fibromyalgia provide multiple shots on goal. If even a few of these programs succeed, Axsome could evolve from a single-product company into a diversified neuroscience pharmaceutical firm. This diversification could reduce reliance on Auvelity and create multiple revenue streams, enhancing the company's long-term value.